| Literature DB >> 35761006 |
Patricia Mondelo-Macía1,2,3, Ana María Rodríguez-Ces1,2,3, María Mercedes Suárez-Cunqueiro1,3, Laura Muinelo Romay4,5.
Abstract
Liquid biopsy has emerged as one of the main pillars for personalized oncology. The term englobes body-fluid samples which contain tumor-derived material such as circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating extracellular vesicles (cEVs). Potential clinical application of liquid biopsy analyses includes cancer screening, detection of minimal residual disease and recurrence, therapy selection, and evaluation of acquired resistance. Despite the great developments of technology focused on circulating biomarkers characterization only cfDNA testing is nowadays implemented for the therapy selection in some advanced tumors. This can be partially explained by the fact that there is still a lack of global standardization of procedures both in the pre-analytical and analytical steps. In the present chapter, we summarize the different strategies for addressing the study of liquid biopsy taking into account their pros and cons to be applied in a clinical context and we also discuss the main technical and clinical challenges in the field of circulating biomarkers and personalized oncology.Entities:
Keywords: Circulating tumor biomarkers; Circulating tumor cells; Extracellular vesicles; Liquid biopsy; Personalized oncology
Mesh：
Substances：
Year: 2022 PMID： 35761006 DOI： 10.1007/978-3-031-04039-9_21
Source DB: PubMed Journal: Adv Exp Med Biol ISSN： 0065-2598 Impact factor: 3.650